Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

BACKGROUND: Atopic dermatitis is a chronic, inflammatory condition causing a substantial burden to patients and caregivers. SHR0302 is an oral, highly selective, Janus kinase 1 inhibitor under investigation for inflammatory skin diseases. OBJECTIVE: The aim of this study was to investigate the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yan, Zhang, Litao, Ding, Yangfeng, Tao, Xiaohua, Ji, Chao, Dong, Xiuqin, Lu, Jianyun, Wu, Liming, Wang, Rupeng, Lu, Qianjin, Goh, Aik Han, Liu, Rongjun, Zhang, Zhiguo, Zhang, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351769/
https://www.ncbi.nlm.nih.gov/pubmed/34374027
http://dx.doi.org/10.1007/s40257-021-00627-2

Ejemplares similares

Ejemplares similares